Literature DB >> 7814873

CD45-cross-linking stimulates IFN-gamma production in NK cells.

F Shen1, X L Xu, L H Graf, A S Chong.   

Abstract

The in vitro demonstration of the ability of NK cells to secrete cytokines prompted in vivo studies that illustrated the importance of NK cell-derived cytokines in regulating immune responses. Cross-linking of CD16 on NK cells can stimulate cytokine production. CD16-independent interactions capable of stimulating cytokine production have also been described, but molecules mediating such stimulations remain to be biochemically defined. We report here that cross-linking of CD45 specifically stimulates IFN-gamma production in human NK cells. The NK cells used were IL-2-activated adherent NK cells and from the NK3.3 cell line. The ability of CD45 mAbs to stimulate NK cells appears not to be dependent on CD16, as CD45 mAbs of both IgG1 and IgG2a isotypes were equally stimulatory, as were F(ab')2 compared with whole anti-CD45 mAbs. Resting NK cells, like T cells, express predominantly CD45RA, whereas IL-2 activated adherent NK cells acquire expression of CD45RO. Abs specific for CD45RO, but not CD45RA, were able to stimulate IFN-gamma production in NK cells. It has been reported that one ligand for CD45RO is CD22 beta. We tested the ability of CD22-expressing transfectants to bind to and stimulate NK cells. Whereas NK cells bound to CD22 alpha and CD22 beta transfectants, this interaction was not inhibited by CD45RO Abs. In addition, neither of the CD22-transfectants were able to stimulate NK3.3 cells to secrete IFN-gamma. These observations collectively suggest that binding of NK3.3 cells to CD22 may be independent of CD45RO on NK3.3 cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814873

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Anti-CD45 isoform antibodies enhance phagocytosis and gene expression of IL-8 and TNF-alpha in human neutrophils by differential suppression on protein tyrosine phosphorylation and p56lck tyrosine kinase.

Authors:  C- L Yu; H-S Yu; K-H Sun; S-C Hsieh; C-Y Tsai
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

2.  Epitope-specific crosslinking of CD45 down-regulates membrane-associated tyrosine phosphatase activity and triggers early signalling events in human activated T cells.

Authors:  François Spertini; Veronique Perret-Menoud; Nathalie Barbier; Talal Chatila; Catherine Barbey; Blaise Corthesy
Journal:  Immunology       Date:  2004-12       Impact factor: 7.397

3.  Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.

Authors:  David G T Hesslein; Rayna Takaki; Michelle L Hermiston; Arthur Weiss; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

4.  Vav in natural killer cells is tyrosine phosphorylated upon cross-linking of Fc gamma RIIIA and is constitutively associated with a serine/threonine kinase.

Authors:  X Xu; A S Chong
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

5.  Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome.

Authors:  J Michałkiewicz; C Barth; K Chrzanowska; H Gregorek; M Syczewska; C M B Weemaes; K Madaliński; J Stachowski
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

6.  Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis.

Authors:  Rekha G Panchal; Ricky L Ulrich; Steven B Bradfute; Douglas Lane; Gordon Ruthel; Tara A Kenny; Patrick L Iversen; Arthur O Anderson; Rick Gussio; William C Raschke; Sina Bavari
Journal:  J Biol Chem       Date:  2009-03-06       Impact factor: 5.157

7.  gamma Interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans.

Authors:  S M Levitz; E A North
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.